InMode Ltd. (INMD) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Devices CIK: 0001742692

Market Cap 3.51

P/E 0.00

P/S 0.00

Div. Yield 0.00

Revenue Growth (1y) (Qtr) 5.32

Add ratio to table...

About

InMode Ltd is a leading global provider of innovative energy-based minimally invasive surgical medical treatment solutions. The company develops and commercializes products using radio frequency energy technology to address face and body contouring medical aesthetics and women's wellness treatments. Its portfolio includes platforms that deliver surgical-grade results under local anesthesia while minimizing risks of scarring downtime pain and complications typically associated with traditional surgical procedures. InMode generates revenue through...

InMode Ltd is a leading global provider of innovative energy-based minimally invasive surgical medical treatment solutions. The company develops and commercializes products using radio frequency energy technology to address face and body contouring medical aesthetics and women's wellness treatments. Its portfolio includes platforms that deliver surgical-grade results under local anesthesia while minimizing risks of scarring downtime pain and complications typically associated with traditional surgical procedures.

InMode generates revenue through the sale of its medical aesthetic platforms handpieces applicators and proprietary software to healthcare providers. Revenue is derived from minimally invasive platforms hands-free platforms and non-invasive platforms across geographic markets with the United States representing the principal market. The company also earns revenue from consumables training services and ongoing support programs provided to physicians who use its products for various aesthetic and wellness procedures.

The company operates through the following segments: Minimally Invasive and Ablative Platforms Non-Invasive Platforms and Hand-Free Platforms.

• Minimally Invasive and Ablative Platforms include products such as BodyTite EmbraceRF Votiva Morpheus8 Envision IgniteRF and AccuTite which utilize bipolar radio frequency energy for subdermal fat remodeling skin tightening and tissue contraction in procedures like liposuction with simultaneous skin tightening face and body contouring and treatment of Genitourinary Syndrome of Menopause.

• Non-Invasive Platforms consist of Contoura Triton ApexRF and Solaria which deliver treatments such as simultaneous fat destruction and skin tightening permanent hair reduction through dual wavelength technology and high-power intense pulsed light for skin rejuvenation and vascular lesion treatment without requiring incisions or anesthesia.

• Hand-Free Platforms comprise EvolveX Evoke Define and Tone which use combinations of bipolar radio frequency and electrical muscle stimulation delivered through applicators mounted on belts or placed over the face or body to provide automated skin tightening fat reduction muscle stimulation and skin rejuvenation treatments without direct physician manipulation during operation.

InMode holds a leading position in the radio frequency energy-based aesthetic solutions market where it competes with companies such as AbbVie Cutera Apyx Medical Venus Concept Sisram Medical Sofwave Medical Cynosure Lumenis BTL Aesthetics and Candela Medical. Its competitive advantages stem from pioneering bipolar radio frequency technology for deep tissue penetration strong brand recognition associated with clinical leadership a broad portfolio of modular platforms extensive regulatory approvals including 37 FDA clearances and a proven track record of innovation supported by over 110 peer-reviewed publications and ongoing third-party clinical studies.

InMode serves plastic and facial surgeons aesthetic surgeons dermatologists and OB/GYNs as its primary customer base. The company also targets newer market opportunities including ENTs urologists ophthalmologists general practitioners and aesthetic clinicians through its expanding product offerings and direct sales force supported by a global network of distributors across more than 100 countries.

Investment thesis

Bull case

InMode’s core technology, Morpheus8, continues to enjoy robust demand within the minimally invasive aesthetic segment, evidenced by a 22% rise in consumables revenue in 2025. This trend indicates that the installed base is generating repeat procedures, a key driver of high margin recurring revenue that can cushion the company against cyclical downturns. Management’s emphasis on product mix evolution—shifting from high‑margin devices to high‑volume consumables—suggests an intentional strategy to lock in long‑term cash flow. The company’s sizeable cash reserves of $555 million provide the flexibility to support marketing and clinical trial spend while maintaining a disciplined share‑repurchase program, enhancing shareholder value.
The forthcoming launch of a Korean‑made Pico laser and an Erbium YAG–Morpheus combination platform represents a strategic expansion into high‑penetration, low‑margin laser markets, which historically dominate aesthetic clinics. By acquiring rather than developing these systems, InMode can leverage proven technology while reducing time‑to‑market, thereby capturing early market share before competitors. The company projects these additions to broaden its addressable market size, especially within the “non‑invasive” segment where demand has doubled in 2025, potentially creating new cross‑sell opportunities between RF and laser solutions. Moreover, the company’s plan to introduce two new platforms annually underscores a commitment to staying ahead of clinical trends, which can translate into sustained competitive differentiation.
Geographic diversification has strengthened InMode’s revenue base, with European sales accounting for 46% of 2025 revenue and a 15% YoY increase in that region. The company’s move to open direct subsidiaries in Argentina and Thailand, replacing underperforming distributors, demonstrates an aggressive approach to capturing emerging markets while improving gross margins by reducing distributor cuts. Management’s confidence in “encouraging signs” in Europe—namely increased revenue and a softer interest‑rate environment—suggests that demand in this region may rebound faster than in North America, providing a counter‑balance to domestic softness. Coupled with the consolidation of North American operations into a single sales organization, InMode is positioned to optimize sales force productivity and channel management, enhancing sales efficiency.
InMode’s gross margin profile remains healthy, with non‑GAAP gross margins hovering around 78% in 2025 and guidance for 2026 at 75–77%. Despite the anticipated margin drag from laser acquisitions and a 15% U.S. import tariff, the company’s high‑margin core product portfolio, including RF platforms, continues to underpin profitability. Management’s disciplined capital allocation—returning $127 million to shareholders and maintaining a $22.7 million operating cash flow—indicates robust free cash flow generation, which can be deployed for R&D, strategic acquisitions, or further share buybacks. This cash generation capability provides a buffer against potential demand contractions and allows InMode to invest in high‑impact clinical trials, such as the dry‑eye bipolar RF indication and women’s health studies, potentially unlocking new revenue streams.

InMode’s core technology, Morpheus8, continues to enjoy robust demand within the minimally invasive aesthetic segment, evidenced by a 22% rise in consumables revenue in 2025. This trend indicates that the installed base is generating repeat procedures, a key driver of high margin recurring revenue that can cushion the company against cyclical downturns. Management’s emphasis on product mix evolution—shifting from high‑margin devices to high‑volume consumables—suggests an intentional strategy to lock in long‑term cash flow. The company’s sizeable cash reserves of $555 million provide the flexibility to support marketing and clinical trial spend while maintaining a disciplined share‑repurchase program, enhancing shareholder value.
The forthcoming launch of a Korean‑made Pico laser and an Erbium YAG–Morpheus combination platform represents a strategic expansion into high‑penetration, low‑margin laser markets, which historically dominate aesthetic clinics. By acquiring rather than developing these systems, InMode can leverage proven technology while reducing time‑to‑market, thereby capturing early market share before competitors. The company projects these additions to broaden its addressable market size, especially within the “non‑invasive” segment where demand has doubled in 2025, potentially creating new cross‑sell opportunities between RF and laser solutions. Moreover, the company’s plan to introduce two new platforms annually underscores a commitment to staying ahead of clinical trends, which can translate into sustained competitive differentiation.
Geographic diversification has strengthened InMode’s revenue base, with European sales accounting for 46% of 2025 revenue and a 15% YoY increase in that region. The company’s move to open direct subsidiaries in Argentina and Thailand, replacing underperforming distributors, demonstrates an aggressive approach to capturing emerging markets while improving gross margins by reducing distributor cuts. Management’s confidence in “encouraging signs” in Europe—namely increased revenue and a softer interest‑rate environment—suggests that demand in this region may rebound faster than in North America, providing a counter‑balance to domestic softness. Coupled with the consolidation of North American operations into a single sales organization, InMode is positioned to optimize sales force productivity and channel management, enhancing sales efficiency.
InMode’s gross margin profile remains healthy, with non‑GAAP gross margins hovering around 78% in 2025 and guidance for 2026 at 75–77%. Despite the anticipated margin drag from laser acquisitions and a 15% U.S. import tariff, the company’s high‑margin core product portfolio, including RF platforms, continues to underpin profitability. Management’s disciplined capital allocation—returning $127 million to shareholders and maintaining a $22.7 million operating cash flow—indicates robust free cash flow generation, which can be deployed for R&D, strategic acquisitions, or further share buybacks. This cash generation capability provides a buffer against potential demand contractions and allows InMode to invest in high‑impact clinical trials, such as the dry‑eye bipolar RF indication and women’s health studies, potentially unlocking new revenue streams.

Bear case

Management’s discussion of strategic alternatives reveals a significant uncertainty about the company’s long‑term value proposition. The CEO’s candid admission that the board is considering “strategic alternatives” and that the process is “not fully involved” in the discussions signals a lack of clear direction and could prompt a market sell‑off if investors fear a potential takeover or breakup. The absence of any concrete timeline or evaluation of these alternatives leaves the market without a defined exit strategy, creating a risk that share prices could deteriorate if a more attractive offer emerges from outside parties. This ambiguity, combined with the company’s historical performance decline (a 6% YoY revenue drop in 2025), may erode investor confidence and depress the stock’s valuation multiple.
The anticipated margin compression from the new laser launches poses a material risk to profitability. The company explicitly acknowledged that the CO2, Pico, and Erbium YAG lasers will be sourced externally and carry a higher cost of goods sold, exacerbated by a 15% U.S. import tariff. While the management expects gross margins to remain around 75% in 2026, this figure is significantly lower than the 78–79% margins achieved on the core RF platforms. If the laser sales fail to achieve the projected volume, the company could experience a double whammy of higher COGS and lower average selling price, squeezing operating margins further and potentially eroding earnings per share below guidance.
Interest‑rate sensitivity is a persistent risk for InMode, as highlighted by the CEO’s observation that leasing rates for capital equipment are a primary driver of sales volumes. The firm relies heavily on leasing programs to finance the purchase of its high‑cost platforms, and any unexpected rebound in interest rates could elevate the effective cost of capital for physicians, dampening demand for new equipment. This sensitivity is amplified by the company’s reliance on a single sales force structure, which may be less adaptable to sudden shifts in consumer willingness to finance procedures. Consequently, a tightening monetary policy could precipitate a sharper decline in new platform deployments, eroding revenue growth and prolonging the “stabilization” year anticipated for 2026.
InMode’s expansion into new markets through direct subsidiaries, while potentially lucrative, also introduces significant operational and regulatory complexities. The CEO’s remarks that the company is establishing subsidiaries in Argentina and Thailand “because we were not very happy with these distributors” suggest a reactive, rather than strategic, approach to market entry. Setting up local manufacturing or sales infrastructure requires substantial capital outlays, local talent acquisition, and compliance with diverse regulatory regimes—all of which can erode cash flow and dilute focus from the core business. Furthermore, the company’s distribution network still accounts for 20% of revenue, indicating that the direct sales model has not yet fully supplanted traditional channels, which may limit growth and margin expansion in the near term.

Management’s discussion of strategic alternatives reveals a significant uncertainty about the company’s long‑term value proposition. The CEO’s candid admission that the board is considering “strategic alternatives” and that the process is “not fully involved” in the discussions signals a lack of clear direction and could prompt a market sell‑off if investors fear a potential takeover or breakup. The absence of any concrete timeline or evaluation of these alternatives leaves the market without a defined exit strategy, creating a risk that share prices could deteriorate if a more attractive offer emerges from outside parties. This ambiguity, combined with the company’s historical performance decline (a 6% YoY revenue drop in 2025), may erode investor confidence and depress the stock’s valuation multiple.
The anticipated margin compression from the new laser launches poses a material risk to profitability. The company explicitly acknowledged that the CO2, Pico, and Erbium YAG lasers will be sourced externally and carry a higher cost of goods sold, exacerbated by a 15% U.S. import tariff. While the management expects gross margins to remain around 75% in 2026, this figure is significantly lower than the 78–79% margins achieved on the core RF platforms. If the laser sales fail to achieve the projected volume, the company could experience a double whammy of higher COGS and lower average selling price, squeezing operating margins further and potentially eroding earnings per share below guidance.
Interest‑rate sensitivity is a persistent risk for InMode, as highlighted by the CEO’s observation that leasing rates for capital equipment are a primary driver of sales volumes. The firm relies heavily on leasing programs to finance the purchase of its high‑cost platforms, and any unexpected rebound in interest rates could elevate the effective cost of capital for physicians, dampening demand for new equipment. This sensitivity is amplified by the company’s reliance on a single sales force structure, which may be less adaptable to sudden shifts in consumer willingness to finance procedures. Consequently, a tightening monetary policy could precipitate a sharper decline in new platform deployments, eroding revenue growth and prolonging the “stabilization” year anticipated for 2026.
InMode’s expansion into new markets through direct subsidiaries, while potentially lucrative, also introduces significant operational and regulatory complexities. The CEO’s remarks that the company is establishing subsidiaries in Argentina and Thailand “because we were not very happy with these distributors” suggest a reactive, rather than strategic, approach to market entry. Setting up local manufacturing or sales infrastructure requires substantial capital outlays, local talent acquisition, and compliance with diverse regulatory regimes—all of which can erode cash flow and dilute focus from the core business. Furthermore, the company’s distribution network still accounts for 20% of revenue, indicating that the direct sales model has not yet fully supplanted traditional channels, which may limit growth and margin expansion in the near term.

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	145.93 Bn	23.33	3.23	34.05 Bn
2	SYK	Stryker Corp	115.71 Bn	34.62	4.58	14.72 Bn
3	MDT	Medtronic plc	97.69 Bn	21.17	2.75	28.07 Bn
4	BSX	Boston Scientific Corp	78.71 Bn	22.00	3.82	11.03 Bn
5	EW	Edwards Lifesciences Corp	47.63 Bn	44.75	7.85	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	13,009.40	1.46	8.07 Bn
7	DXCM	Dexcom Inc	22.72 Bn	24.58	4.72	-
8	STE	STERIS plc	20.71 Bn	29.06	3.55	1.90 Bn

Research Tools

InMode Ltd. (NASDAQ: INMD)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Research Tools

InMode Ltd. (NASDAQ: INMD)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password